Skip to content
10-Q

Quarterly Report

INTEGRATED BIOPHARMA INC INBP

0001437749-26-015899

← back to feed
Filed
May 8, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2026 · May 8, 2026 31.06M sh
Shares Diluted Q3 2026 · Mar 31, 2026 31.06M sh
Shares Diluted Q3 2026 · Mar 31, 2026 31.06M sh
Shares Diluted Q3 2026 · Mar 31, 2025 31.51M sh
Shares Diluted Q3 2026 · Mar 31, 2025 30.96M sh
Capex Q3 2026 · Mar 31, 2026 $197K
Capex Q3 2026 · Mar 31, 2025 $201K
Operating Cash Flow Q3 2026 · Mar 31, 2026 $2.44M
Operating Cash Flow Q3 2026 · Mar 31, 2025 $1.47M
Cash And Equivalents Q3 2026 · Mar 31, 2026 $5.83M
Cash And Equivalents Q3 2026 · Jun 30, 2025 $3.62M
Stockholders Equity Q3 2026 · Mar 31, 2026 $18.98M
Stockholders Equity Q3 2026 · Dec 31, 2025 $19.77M
Stockholders Equity Q3 2026 · Sep 30, 2025 $20.49M
Stockholders Equity Q3 2026 · Jun 30, 2025 $20.32M
Stockholders Equity Q3 2026 · Mar 31, 2025 $20.38M
Stockholders Equity restated Q3 2026 · Dec 31, 2024 $19.73K
Stockholders Equity restated Q3 2026 · Sep 30, 2024 $18.55M
Stockholders Equity Q3 2026 · Jun 30, 2024 $19.24M
Current Liabilities Q3 2026 · Mar 31, 2026 $5.53M
Current Liabilities Q3 2026 · Jun 30, 2025 $4.25M
Total Liabilities Q3 2026 · Mar 31, 2026 $7.69M
Total Liabilities Q3 2026 · Jun 30, 2025 $4.58M
Current Assets Q3 2026 · Mar 31, 2026 $17.97M
Current Assets Q3 2026 · Jun 30, 2025 $18.76M
Total Assets Q3 2026 · Mar 31, 2026 $26.67M
Total Assets Q3 2026 · Jun 30, 2025 $24.9M
Eps Diluted Q3 2026 · Mar 31, 2026 −$0.03
Eps Diluted Q3 2026 · Mar 31, 2026 −$0.05
Eps Diluted Q3 2026 · Mar 31, 2025 $0.02
Eps Diluted Q3 2026 · Mar 31, 2025 $0.03
Eps Basic Q3 2026 · Mar 31, 2026 −$0.03
Eps Basic Q3 2026 · Mar 31, 2026 −$0.05
Eps Basic Q3 2026 · Mar 31, 2025 $0.02
Eps Basic Q3 2026 · Mar 31, 2025 $0.03
Sga Expense Q3 2026 · Mar 31, 2026 $809K
Sga Expense Q3 2026 · Mar 31, 2026 $2.61M
Sga Expense Q3 2026 · Mar 31, 2025 $812K
Sga Expense Q3 2026 · Mar 31, 2025 $2.66M
Net Income Q3 2026 · Mar 31, 2026 −$837K
Net Income Q3 2026 · Mar 31, 2026 −$1.48M
Net Income Q3 2026 · Dec 31, 2025 −$762K
Net Income Q3 2026 · Sep 30, 2025 $123K
Net Income Q3 2026 · Mar 31, 2025 $611K
Net Income Q3 2026 · Mar 31, 2025 $986K
Net Income Q3 2026 · Dec 31, 2024 $116K
Net Income Q3 2026 · Sep 30, 2024 $259K
Operating Income Q3 2026 · Mar 31, 2026 −$1.09M
Operating Income Q3 2026 · Mar 31, 2026 −$1.84M
Operating Income Q3 2026 · Mar 31, 2025 $739K
Operating Income Q3 2026 · Mar 31, 2025 $1.43M
Gross Profit Q3 2026 · Mar 31, 2026 −$276K
Gross Profit Q3 2026 · Mar 31, 2026 $772K
Gross Profit Q3 2026 · Mar 31, 2025 $1.55M
Gross Profit Q3 2026 · Mar 31, 2025 $4.09M
Cost Of Revenue Q3 2026 · Mar 31, 2026 $10.38M
Cost Of Revenue Q3 2026 · Mar 31, 2026 $33.3M
Cost Of Revenue Q3 2026 · Mar 31, 2025 $12.4M
Cost Of Revenue Q3 2026 · Mar 31, 2025 $36.09M